1McLaughlin P,Cahanillas F,Grillo-Lopez AZ,et al.IDEC-C2B8 anti -CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma[].Blood.1996
2Demidem A,Hanna N,Marihanab H,et al.Chimeric anti CD20 antibody ( IDEC-C2B8 ) is apoptotic and sensitizes drug-resistant human B-cell lymphoma and AIDS-related lymphomas to the cytotoxic effect of CDDP, VP16 and toxins[].The FASEB Journal.1995
3Maloney DG,Grillo-Lopez AJ,White CA,et al.IDEC -C2B8( Rituximab ) monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’ s lymphoma[].Blood.1997
同被引文献3
1[1]Demidem A. , Hanna N, Marihanab H, et al. Chimeric antiCD20 antibody (IDEC-28) is apoptoticand sensitizes drug-resistant human B-cell lymphoma and AIDS- related lymphomas to the cytotoxic effect of CDDP, VP16 and toxins. FASEB, 1995,9:A206.
2[2]Maloney DO, Grillo-Lopez A J, White CA , et al. IDEC--C2B8 (Rituximab) monoclonal antibody therapy in a ptients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 1997,90:2188-2195.
3[3]MeLaughlin P, Cahanillax F, Grillo- Lope. z AZ, et al.IDEC- C2B8 anti- CD20 antibody: final report on a phase Ⅲ pivotal trial in patients with relapsed low-grade or folliculalymphorna. Blood, 1996,88(Suppl 1) : 90a.
